Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients.
Ramirez-Carracedo et al. Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.
Biomolecules. Aug 9;10(8):1167. doi:10.3390/biom10081167.
Jul, 2020
Authorization to start the APRIL trial
The Spanish regulatory agency has approved the APRIL clinical trial, a Phase 1b/2a study to assess the safety and efficacy of ApTOLL in acute ischemic stroke patients.
Jul, 2020
RETOS funding for the ApTOLL stroke program
Consortium formed by aptaTargets and the Vall d’Hebron Hospital (VHIR) have been awarded by the Retos-Colaboracion program. The project and the €1,4 million will be focused on the clinical development of ApTOLL. The Retos-Colaboracion is a collaborative program of the Spanish Ministry of Science and Innovation, within the objective of promoting the technological development, innovation, and research.
(RTC2019-006795-1)
Jun, 2020
Torres Quevedo grant
aptaTargetsgets a grant from the Torres Quevedo Program.
(PTQ2019-010411)
Mar, 2020
aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers
aptaTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
Jun, 2019
EIT Health
aptaTargets has been awarded with the Bridgehead Program.
Jun, 2019
First Patient in the ApTOLL-FIH-01 trial: a Phase I trial in healthy volunteers
aptaTargets has started the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.
Dec, 2018
aptaTargets: finalist award at the EIT Health annual meeting 2018
aptaTargets attended the EIT health annual meeting held at the IESE Business School in Barcelona and was awarded with the finalist award of the Spanish Health Catapult program. aptaTargets is part of the EIT Health community and during 2018 has also been awarded with the EIT Health Headstart program.
Dec, 2018
aptaTargets gets new funding from the RETOS-program for exploring inflammatory pathologies
A Consortium led by aptaTargets has been awarded with public funding from the RETOS program for exploring new indications for ApTOLL, a DNA aptamer targeting TLR4 with an anti-inflammatory effect. The Consortium RETOS-SafeTOLL (RTC-2017-6283-1) is also composed by the Neurovascular Research Unit (Complutense University, Madrid) and the Institute of Biomedical Research (UAM-CSIC, Madrid) and has a total budget of 503,800 EU.
(FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación/ _RTC-2017-6283-1)
Dec, 2018
RETOS funding for the ApTOLL stroke program
aptaTargets is the leader of the NeuroToll project, aiming to the clinical development of ApTOLL, an innovative neuroprotective drug for the acute treatment of stroke. The project focuses in stroke program, advancing from late preclinical phase and up to clinical trials Phase II in stroke patients. The consortium is formed by aptaTargets along with several hospitals of reference in the stroke field, such as Germans Trias i Pujol (HGTiP, Barcelona), La Princesa (HULP, Madrid), Virgen del Rocio and Macarena (FISEVI, Sevilla). The project has an aggregated budget of around 3.1 M EU.
(FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación/ _RTC-2017-6651-1)
Nov, 2018
aptaTargets: awarded by Doctorado Industrial Program
The project involves a doctoral program aiming the study of further application of ApTOLL in Multiple Sclerosis.
Sep, 2018
EIT Health
aptaTargets has been awarded with the Headstart Program.
Mar, 2018
aptaTargets gets funds from NEOTEC Program
The Spanish Centre for the Development of Industrial Technology (CDTI) has granted aptaTargets with funds from the Neotec Program. aptaTargets aims to advance in the pre-clinical and clinical development of ApToll (a molecule based on aptamer technology and targeting inflammation) in acute ischemic stroke and other indications (myocardial infarction and Multiple Sclerosis).
(EXP-00112737/SNEO-20171153)
Jan, 2016
aptaTargets closes €2.7- million round of funding for new stroke treatment
'la Caixa', throught their venture capital arm Caixa Capital Risc, and Inveready have invested €2.7 million in aptaTargets, which will allow this biopharmaceutical company to complete the preclinical phase and move into phase I and II clinical trials on its first drug candidate (ApTOLL) to treat acute ischemic stroke. Press release
Dec, 2015
ApTOLL gets funds from Retos-2015 Program
The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company aptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.
We use our own and third-party cookies to improve our services and show commercials related to your own preferences through the analysis of your browsing habits. Clicking Accept entails your acceptance in using them.
You can change this configuration or obtain additional information on legal warning.ACCEPT
